Skip to main content
. 2023 Nov 3;6(11):e2341033. doi: 10.1001/jamanetworkopen.2023.41033

Table 1. Characteristics of Study Population.

Characteristic Received dexmedetomidine (n = 384) Did not receive dexmedetomidine (n = 374 058)
Gestational age, median (IQR), wk 27 (25-31) 34 (32-35)
Birth weight, median (IQR), kg 0.89 (0.66-1.56) 2.02 (1.58-2.42)
Sex, No. (%)
Male 226 (58.9) 201 743 (53.9)
Female 158 (41.1) 172 226 (46.0)
Missing 0 89 (0.1)
Length of hospitalization, median (IQR), d 71 (23-117) 18 (11-34)
Race and ethnicity, No. (%)a
Black 121 (31.5) 77 687 (20.8)
Hispanic 52 (13.5) 73 846 (19.7)
White 177 (46.1) 175 725 (47.0)
Other 23 (6.0) 23 583 (6.3)
Missing 11 (2.9) 23 217 (6.2)
Maternal age group, No. (%), y
≤19 15 (3.9) 23 791 (6.4)
20-29 211 (54.9) 174 942 (46.8)
30-39 145 (37.8) 156 664 (41.9)
≥40 10 (2.6) 17 244 (4.6)
Missing 3 (0.8) 1417 (0.4)
Drug exposure, No. (%)
Fentanyl 154 (40.1) 16 713 (4.5)
Morphine 176 (45.8) 14 920 (4.0)
Clonidine 48 (12.5) 437 (0.1)
Any opioid 245 (63.8) 28 194 (7.5)
Mechanical ventilation, median (IQR), d 9 (2-36) 0 (0-0)
a

Other indicates not identified as Black, Hispanic, or White. The Other group is presented the way the database is organized.